Russia’s N.F. Gamalei Epidemiology and Microbiology Research Institute has launched clinical trials of anti-Ebola vaccines that will necessitate 4.8 million rubles (about $75,000), the official portal for government procurement said on Friday.
Pre-emptive vaccines against Ebola – Gum Evak and Gum Evak Combi are ready for human trials, the portal said. The main aim of the research is to assess post-vaccination immunity in patients at different points of time after inoculation. Under the forecasts, the research is to end by December 2017.
It was also said that the Gamalei institute had insured volunteers in clinical trials of the registered vaccines. Two million rubles ($31,282) would be paid if a volunteer died. Should a volunteer’s health be damaged leading to a first degree disability, the patient would receive 1.5 million rubles ($26,461), while a second-degree disability would enable him to be awarded one million rubles. However, in cases of third degree disability, the patient would receive 500,000 rubles.
The World Health Organization presented Russia’s pre-emptive vaccines against Ebola – Gum Evak and Gum Avak Combi – in Geneva on February 15. Russia launched work on vaccines in October 2014, and within 15 months, two vaccines were introduced showing maximum efficiency, full safety and high tolerability.
At the moment, the Russian vaccine is the only one that has been registered.
According to the World Health Organization (WHO), more than 11,300 people have died from Ebola in West Africa, primarily in Guinea, Sierra Leone and Liberia. More than 28,600 were infected.
Source: TASS
